Renfu Pharmaceutical announced that the holding subsidiary Yichang Renfu recently received the “Drug Registration Certificate” for Lysiming transdermal patches approved and issued by the State Drug Administration. Lisimin transdermal patches have been approved for use in the treatment of mild to moderate symptoms of Alzheimer's disease. Yichang Renfu submitted a marketing license application for Lisiming transdermal patch to the State Drug Administration in March 2023 and was accepted. Up to now, the total R&D investment for the project is about RMB 19 million.

Renfu Pharmaceutical announced that the holding subsidiary Yichang Renfu recently received the “Drug Registration Certificate” for Lysiming transdermal patches approved and issued by the State Drug Administration. Lisimin transdermal patches have been approved for use in the treatment of mild to moderate symptoms of Alzheimer's disease. Yichang Renfu submitted a marketing license application for Lisiming transdermal patch to the State Drug Administration in March 2023 and was accepted. Up to now, the total R&D investment for the project is about RMB 19 million.